Pre-IPO Asset Impairment Testing and Disclosure Requirements

The Hong Kong Stock Exchange (HKEX) published its 2024 annual review of listing decisions on 15 January 2025, revealing that asset impairment testing was the single most common area of deficiency in pre-IPO financial due diligence, cited in 23 of 48 rejected applications for the Main Board and GEM. This marks a 64% increase from 2023, when impairment issues were flagged in only 14 of 52 rejections. The trend is not coincidental. With HKEX Listing Rule amendments effective 1 January 2025 requiring enhanced financial disclosure in listing documents under Chapter 9, and the Securities and Futures Commission (SFC) intensifying its scrutiny of sponsor work under the Code of Conduct for Persons Licensed by or Registered with the SFC (the SFC Code), particularly paragraphs 17.1 to 17.7 on due diligence, impairment testing has moved from a routine accounting exercise to a critical regulatory gate. For CFOs, company secretaries, and legal advisors preparing for a Hong Kong IPO, the margin for error on goodwill, intangible assets, and long-lived asset impairments has effectively vanished. The HKEX now expects listing applicants to demonstrate not only that impairment models comply with Hong Kong Financial Reporting Standards (HKFRS), but that the assumptions underlying those models are directly traceable to the applicant’s business model, market conditions, and forward-looking forecasts. Failure to do so invites substantive follow-up questions, extended vetting timelines, and in the worst case, a formal return of the application under Listing Decision LD43-3.

The Regulatory Framework: HKFRS, HKEX, and SFC Convergence

HKFRS Requirements for Pre-IPO Impairment Testing

The foundation of all impairment testing in a Hong Kong listing context is HKAS 36 Impairment of Assets, which mandates that an entity assess at each reporting date whether there is any indication that an asset may be impaired. For goodwill and intangible assets with indefinite useful lives, HKAS 36 paragraph 10 requires an annual impairment test irrespective of whether impairment indicators exist. This annual test must be performed at the level of the cash-generating unit (CGU) or group of CGUs to which the goodwill has been allocated under HKAS 36 paragraph 80. For pre-IPO applicants, this creates a specific compliance burden: the impairment test must be completed for the most recent financial year-end prior to the submission of the listing application (Form A1) under HKEX Listing Rule 9.11(23a). The HKEX has clarified in Listing Decision HKEX-LD92-2018 that a “look-back” impairment test covering the three most recent financial years is expected, with particular attention to any impairment losses recognised or reversed during that period.

HKEX Listing Rules on Financial Disclosure in Prospectuses

HKEX Listing Rule 11.07 requires that the accountants’ report included in the prospectus comply with HKFRS, and by extension, HKAS 36. More specifically, Appendix D1, paragraph 27(2) of the Main Board Listing Rules requires disclosure of the key assumptions used in impairment testing, including growth rates, discount rates, and the period over which cash flows are projected. The HKEX’s “Guidance on Disclosure of Financial Information in Listing Documents” (HKEX-GL86-16), updated in December 2024, explicitly states that listing applicants must provide a sensitivity analysis showing the impact of a reasonably possible change in a key assumption on the recoverable amount. The guidance further warns that where the headroom (the excess of recoverable amount over carrying amount) is less than 10% of the carrying amount, the HKEX will require detailed narrative explaining why the assumption is appropriate and how it was derived. This threshold, while not codified in the Listing Rules themselves, has been consistently applied in practice since 2022.

SFC Sponsor Oversight and Due Diligence Standards

The SFC’s Code of Conduct, paragraph 17.6, imposes a specific duty on sponsors to ensure that the listing document does not contain any untrue statement of a material fact. In the context of impairment testing, this means the sponsor must independently verify the assumptions used in the applicant’s impairment model. The SFC’s “Guidance Note on Due Diligence for Sponsors” (July 2023 update) requires sponsors to obtain and review the applicant’s internal impairment testing documentation, including board minutes approving the assumptions, management’s cash flow forecasts, and external valuation reports where applicable. The SFC has taken enforcement action against sponsors for inadequate impairment due diligence: in SFC v. [Redacted] (2023), a sponsor was fined HKD 8 million for failing to challenge management’s overly optimistic revenue growth assumptions used in goodwill impairment testing for a pre-IPO applicant in the retail sector. This case establishes a clear precedent: the sponsor cannot simply accept management’s impairment model; it must independently stress-test the assumptions.

Practical Implementation: Building a Robust Impairment Model

Defining Cash-Generating Units and Allocating Goodwill

The first and most consequential decision in impairment testing is the identification of CGUs. Under HKAS 36 paragraph 66, a CGU is the smallest group of assets that generates cash inflows from continuing use that are largely independent of the cash inflows from other assets or groups of assets. For pre-IPO applicants with multiple business lines, geographic segments, or product categories, this determination is rarely straightforward. The HKEX has rejected listing applications where goodwill was allocated to an excessively broad CGU, thereby masking impairment in underperforming segments. In Listing Decision HKEX-LD112-2020, the Exchange required an applicant to re-segment its CGUs from a single entity-wide unit to three separate CGUs corresponding to its three distinct product lines, resulting in an impairment charge of HKD 45 million in one CGU that had previously been hidden. The lesson is clear: CGU segmentation must reflect how management monitors the business, and the allocation of goodwill must follow the methodology used for internal reporting under HKFRS 8 Operating Segments.

Selecting Valuation Methodologies: Value in Use vs. Fair Value Less Costs of Disposal

HKAS 36 permits two approaches to determining recoverable amount: value in use (VIU) and fair value less costs of disposal (FVLCD). For pre-IPO applicants, VIU is the more commonly used method because it relies on entity-specific cash flow projections rather than market-based comparables, which may be limited for private companies. Under HKAS 36 paragraph 30, VIU is calculated using pre-tax cash flow projections based on the most recent financial budgets approved by management, covering a maximum period of five years unless a longer period can be justified. The discount rate applied must be a pre-tax rate that reflects the current market assessment of the time value of money and the risks specific to the asset. The HKEX has observed in its 2024 review that discount rates used by applicants ranged from 8% to 22%, with the median at 13.5%, and that deviations from industry norms require explicit justification. For example, an applicant in the technology sector using a discount rate below 10% would need to demonstrate that its cost of capital is genuinely lower than peers, perhaps through reference to its actual weighted average cost of capital (WACC) calculated from recent debt and equity financing transactions.

Sensitivity Analysis and Headroom Management

The sensitivity analysis required by HKEX-GL86-16 is not a mere formality. The HKEX expects the analysis to cover all key assumptions: revenue growth rate, gross margin, discount rate, and terminal value growth rate. The analysis must show the impact of a 1% change in each assumption on the recoverable amount, and where the headroom is less than 10% of the carrying amount, the applicant must explain why the chosen assumption is the most appropriate estimate. In practice, the most common trigger for HKEX follow-up questions is a headroom of less than 5%. For applicants in this zone, the HKEX will typically request a third-party valuation report, a written confirmation from the sponsor that it has independently verified the assumptions, and a detailed board paper showing the approval process. CFOs should note that the HKEX has the power to require an impairment charge to be recognised in the pro forma financial statements included in the prospectus, even if the applicant’s statutory accounts did not record an impairment, if the Exchange determines that the assumptions were not supportable.

Disclosure in the Prospectus: What the HKEX Expects

The Accountants’ Report and Pro Forma Financial Information

Under HKEX Listing Rule 11.07, the accountants’ report must include a note on impairment testing for each period presented. The disclosure must state the carrying amount of goodwill and intangible assets, the CGU to which they are allocated, the basis of the recoverable amount (VIU or FVLCD), and the key assumptions. For the pro forma financial information required under Listing Rule 4.29, any impairment adjustments that would have been required had the listing structure been in place at the relevant date must be shown. The HKEX’s 2024 review found that 18% of applicants failed to disclose the discount rate used in their impairment model in the accountants’ report, a deficiency that the Exchange now treats as a material omission requiring a revised filing.

The “Risk Factors” Section and Forward-Looking Statements

The prospectus risk factors section must address the risk of future impairment. Standard practice, as outlined in the HKEX’s “Guidance on Disclosure of Risk Factors” (HKEX-GL53-13), requires a specific risk factor for each material intangible asset or goodwill balance. The risk factor should quantify the carrying amount, state the headroom percentage, and describe the assumptions that, if not met, could trigger an impairment. For example: “As at 31 December 2024, the carrying amount of goodwill allocated to the [X] CGU was HKD [Y] million, representing [Z]% of total net assets. The recoverable amount was determined using value in use calculations based on a pre-tax discount rate of [W]% and a terminal growth rate of [V]%. If the actual revenue growth rate were to fall by 2 percentage points below the projected rate, the recoverable amount would be reduced to approximately HKD [U] million, resulting in an impairment charge of HKD [T] million.” This level of specificity is now expected, not optional.

Management Discussion and Analysis (MD&A)

The MD&A section of the prospectus under Listing Rule 11.07 must discuss the key drivers of the impairment testing results. This includes an explanation of why the assumptions were chosen, how they compare to historical performance, and what external market data supports them. The HKEX has specifically criticised applicants that simply repeat the assumptions from the accountants’ report without providing narrative context. In its 2024 observations, the Exchange noted that the most effective MD&A disclosures included a table showing the actual performance of the CGU against the prior year’s projections, thereby demonstrating the reliability of management’s forecasting process. Where actual performance has consistently fallen short of projections, the HKEX will expect a downward revision of future assumptions and, potentially, an impairment charge.

Cross-Border Considerations and Structuring Implications

Impairment Testing for VIE Structures and PRC Operating Entities

For pre-IPO applicants using variable interest entity (VIE) structures to consolidate PRC operating companies, impairment testing presents unique challenges. Under HKAS 36, the CGU must include the VIE and its underlying operating entities, but the goodwill arising from the VIE structure is typically allocated to the CGU that represents the entire consolidated group. The HKEX has expressed concern in Listing Decision HKEX-LD124-2021 that VIE structures often mask impairment at the operating entity level because cash flows are upstreamed through service agreements rather than being independently generated. The Exchange now requires applicants with VIE structures to perform impairment testing at the level of each individual operating entity, not just the consolidated group, and to disclose the results of these disaggregated tests in the prospectus. This requirement has resulted in several applicants recognising impairment charges at the VIE subsidiary level that were not apparent at the consolidated level.

Tax Implications of Impairment Recognition in Hong Kong and PRC

The recognition of an impairment loss has direct tax consequences that must be considered in the pre-IPO financial planning. Under Hong Kong’s Inland Revenue Ordinance (Cap. 112), impairment losses on goodwill and intangible assets are not deductible for profits tax purposes unless the asset is sold or the business is discontinued. In the PRC, under the Enterprise Income Tax Law (EIT Law), impairment losses are generally not deductible unless they meet specific criteria under the Ministry of Finance’s regulations. This creates a timing difference that results in a deferred tax asset under HKAS 12 Income Taxes. The recognition of a deferred tax asset on impairment losses requires the applicant to demonstrate that sufficient future taxable profits will be available against which the deductible temporary difference can be utilised. For pre-IPO applicants with a history of losses, this is a significant hurdle. The SFC has indicated in its 2024 thematic review of deferred tax assets that it expects sponsors to independently verify management’s forecasts of future taxable profits, particularly where the deferred tax asset exceeds 10% of total assets.

Impact on Valuation and Pricing

Impairment charges recognised in the pre-IPO period directly affect the applicant’s net asset value and earnings history, both of which are inputs into the IPO valuation. For applicants using a price-to-book (P/B) multiple as a primary valuation methodology, a material impairment charge reduces book value and increases the implied P/B multiple, potentially making the shares less attractive to value-oriented investors. Conversely, for applicants using a price-to-earnings (P/E) multiple, an impairment charge reduces reported earnings, increasing the P/E multiple. The HKEX requires that any impairment charge recognised in the three years preceding the listing application be disclosed in the prospectus and explained in the MD&A. In practice, many applicants choose to recognise impairment charges in the earliest of the three years presented to minimise the impact on the most recent year’s earnings, which is the primary reference point for IPO pricing. This approach is permissible under HKFRS, but the HKEX will scrutinise the timing to ensure it is not an attempt to manipulate the earnings trajectory.

Actionable Takeaways

1. Complete impairment testing for all CGUs at least six months before filing Form A1, and engage an external valuation specialist to prepare a report that can be shared with the sponsor and the HKEX, as the Exchange now routinely requests third-party valuation support for any headroom below 15% of carrying amount.

2. Disaggregate CGU segmentation to the level at which management makes operational decisions, and ensure that the allocation of goodwill follows the internal reporting structure under HKFRS 8, as the HKEX has rejected applications where overly broad CGU definitions masked impairment in underperforming segments.

3. Prepare a sensitivity analysis covering at least a 1% change in each key assumption, and include a written explanation for any assumption that results in headroom of less than 10%, as the HKEX will treat this as a material disclosure item requiring specific justification in the prospectus.

4. For VIE structures, perform impairment testing at the individual operating entity level, and disclose the results in the prospectus alongside the consolidated test, as the HKEX now considers this a minimum requirement under Listing Decision HKEX-LD124-2021.

5. Coordinate the impairment testing timeline with the IPO valuation process, and consider recognising any necessary impairment charges in the earliest of the three financial years presented in the accountants’ report to minimise the impact on the most recent year’s earnings, which is the primary reference point for the IPO pricing range.